Suppr超能文献

患者安全实情调查员:将颈椎硬膜外注射风险降至最低。

FACTFINDERS FOR PATIENT SAFETY: Minimizing risks with cervical epidural injections.

作者信息

Holder Eric K, Lee Haewon, Raghunandan Aditya, Marshall Benjamin, Michalik Adam, Nguyen Minh, Saffarian Mathew, Schneider Byron J, Smith Clark C, Tiegs-Heiden Christin A, Zheng Patricia, Patel Jaymin, Levi David

机构信息

Yale University School of Medicine, Department of Orthopedics and Rehabilitation, New Haven, CT, USA.

Jefferson Moss-Magee Rehab, Philadelphia, PA, USA.

出版信息

Interv Pain Med. 2024 Aug 27;3(3):100430. doi: 10.1016/j.inpm.2024.100430. eCollection 2024 Sep.

Abstract

This series of FactFinders presents a brief summary of the evidence and outlines recommendations to minimize risks associated with cervical epidural injections. Evidence in support of the following facts is presented. - 1) CILESIs should be performed at C6-C7 or below, with C7-T1 as the preferred access point due to the more generous dorsal epidural space at this level compared to the more cephalad interlaminar segments. This reduces the risk of the minor complication of dural puncture and the major complication of spinal cord injury due to inadvertent needle placement. 2) LF gaps are most prevalent in the midline cervical spine. This can result in diminished tactile feedback with loss of resistance (LOR), increasing the risk for inadvertent dural puncture or spinal cord injury. Based on current evidence, needle placement in the paramedian portion of the interlaminar space is safest to avoid LF gaps. 3) An optimal AP trajectory view and the physician's ability to discern engagement in the LF and subsequent LOR are crucial. Confirmation of minimal needle insertion depth relative to the ventral margin of the lamina with either a lateral or contralateral oblique (CLO) safety view is critical to minimize the risk of inadvertently inserting the needle too ventral. 4) There have been closed claims and case reports of patients who have suffered catastrophic neurologic injuries while receiving CILESIs under deep sedation. If sedation is administered, the least amount necessary should be utilized to ensure the patient can provide verbal feedback during the procedure. 5) CILESIs are an elective procedure; therefore, necessity and likelihood of benefit must be foremost considerations. Current guidelines recommend holding ACAP therapy before CILESIs due to the potentially catastrophic complications associated with epidural hematoma (EH) formation. However, there is also a risk of severe systemic complications with ceasing ACAP in specific clinical scenarios. The treating physician is obligated to determine if the procedure is indicated and can ultimately decide to delay the intervention or not perform the procedure if the benefit does not outweigh the risks. -- Variations in vascular anatomy may warrant a modified approach to CTFESI. Preprocedural review of cross-sectional imaging can provide critical information for safe injection angle planning specific to individual patients and may help to decrease the risk of unintended vascular events with potentially catastrophic outcomes. Safe performance of a CTFESI procedure requires the ability to detect inadvertent arterial injection. Contrast medium placed into the epidural space and/or along the exiting spinal nerves during an initial CTFESI may obscure the detection of inadvertent cannulation of a radiculomedullary artery by a subsequent CTFESI. While no available literature directly addresses the potential risk that exists with a multi-level or bilateral CTFESI, caution is still warranted.

摘要

本系列《事实发现者》简要总结了相关证据,并概述了将颈椎硬膜外注射相关风险降至最低的建议。以下是支持相关事实的证据。- 1)颈椎硬膜外间隙注射(CILESIs)应在C6 - C7或更低水平进行,首选C7 - T1作为穿刺点,因为与更靠头侧的椎间隙相比,该水平的背侧硬膜外间隙更宽。这可降低因意外针刺导致硬膜穿刺小并发症和脊髓损伤大并发症的风险。2)韧带间隙(LF)在颈椎中线最为常见。这可能导致触觉反馈减弱和阻力消失(LOR),增加意外硬膜穿刺或脊髓损伤的风险。根据现有证据,在椎间隙的旁正中部分进针最安全,可避免韧带间隙。3)最佳的前后位(AP)轨迹视图以及医生辨别进入韧带间隙和随后阻力消失的能力至关重要。通过侧位或对侧斜位(CLO)安全视图确认相对于椎板腹侧边缘的最小进针深度,对于将意外进针过腹侧的风险降至最低至关重要。4)有关于患者在深度镇静下接受颈椎硬膜外间隙注射时遭受灾难性神经损伤的非公开索赔和病例报告。如果使用镇静剂,应使用最低必要剂量,以确保患者在操作过程中能够提供言语反馈。5)颈椎硬膜外间隙注射是一种选择性操作;因此,必要性和获益可能性必须是首要考虑因素。当前指南建议在颈椎硬膜外间隙注射前停用抗血小板和抗凝药物(ACAP)治疗,因为硬膜外血肿(EH)形成可能会引发灾难性并发症。然而,在特定临床情况下停用ACAP也存在严重全身并发症的风险。主治医生有责任确定该操作是否适用,如果获益不大于风险,最终可决定推迟干预或不进行该操作。- 血管解剖结构的变异可能需要对颈椎经椎间孔硬膜外类固醇注射(CTFESI)采用改良方法。术前对横断面成像的评估可为针对个体患者的安全注射角度规划提供关键信息,并可能有助于降低发生意外血管事件及潜在灾难性后果的风险。安全进行颈椎经椎间孔硬膜外类固醇注射操作需要具备检测意外动脉注射的能力。在初次颈椎经椎间孔硬膜外类固醇注射期间注入硬膜外间隙和/或沿脊神经穿出部位的造影剂,可能会掩盖后续颈椎经椎间孔硬膜外类固醇注射时意外插入神经根髓动脉的检测。虽然尚无现有文献直接论述多级或双侧颈椎经椎间孔硬膜外类固醇注射存在的潜在风险,但仍需谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f148/11536293/6bb8d50aaf17/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验